Usage Examples
- The 351(k) package leans on analytical comparability; the clinical study only has to close the residual uncertainty.
- We are not filing for interchangeability in the first cycle, so pharmacy substitution is off the table at launch.
- The biosimilar cannot be submitted until year four and cannot be licensed effective until year twelve.
What is Biosimilar?
A biosimilar is a biological product licensed under section 351(k) of the Public Health Service Act as highly similar to an existing reference product, with no clinically meaningful differences in safety, purity, and potency.
Biosimilars exist because biologics are large, structurally complex molecules that no second manufacturer can reproduce exactly. Before the abbreviated pathway existed, a competing version of an approved biologic needed a full standalone application with its own safety and efficacy program. The Biologics Price Competition and Innovation Act created section 351(k) so a sponsor can instead rely on the reference product.
A biosimilar covers only what the reference product already covers. The statute limits a 351(k) application to the same mechanism of action, route of administration, dosage form, and strength, and to conditions of use already licensed for the reference product. A biosimilar is therefore not a new indication, a reformulation, or an improved molecule; those require standalone 351(a) licensure.
Biosimilar development inverts the usual evidence pyramid. Sponsors invest in analytical characterization first, then add toxicity assessment and comparative clinical work covering immunogenicity and pharmacokinetics or pharmacodynamics, sized to resolve whatever residual uncertainty the analytics leave. Interchangeability is pursued separately, as an additional statutory finding about switching risk, and it bears on substitution at the pharmacy rather than on biosimilarity itself.
Not to be confused with
- Generic drug
- a generic is chemically identical to its reference listed drug and is approved under section 505(j) of the FD&C Act on bioequivalence. A biosimilar can only be highly similar, so it is licensed under a different statute on a much larger evidence package.
- Interchangeable biosimilar
- every interchangeable product is a biosimilar, but not the reverse. Interchangeability is an extra finding under 42 U.S.C. 262(k)(4) about the risk of alternating or switching, made on top of the biosimilarity showing.
- Biobetter
- a biobetter is deliberately engineered to outperform the reference product. That improvement is precisely what disqualifies it from 351(k), because the standard is high similarity, not superiority.
- Purple Book vs Orange Book
- the Purple Book is FDA's database of licensed biological products, including biosimilar and interchangeable status. The Orange Book covers drugs approved under the FD&C Act with therapeutic-equivalence codes, which do not apply to biologics.
The obligations below are statutory, not guidance, and they define the outer edge of what a 351(k) filing can claim.
What you must do
- 1Submit analytical studies showing high similarity to the reference product, an assessment of toxicity, and a clinical study or studies covering immunogenicity and pharmacokinetics or pharmacodynamics42 U.S.C. 262(k)(2)(A)(i)
- 2Match the reference product on mechanism of action, route of administration, dosage form, and strength, and limit the application to conditions of use already licensed for the reference product42 U.S.C. 262(k)(2)(A)(i)
- 3Demonstrate no clinically meaningful differences from the reference product in safety, purity, and potency, notwithstanding minor differences in clinically inactive components42 U.S.C. 262(i)(2)
- 4To claim interchangeability, additionally show the product can be expected to produce the same clinical result as the reference product, and for products administered more than once, that alternating or switching does not raise the risk42 U.S.C. 262(k)(4)
- 5Hold the application until 4 years after the reference product was first licensed, and plan launch around licensure that cannot be made effective until 12 years after that date42 U.S.C. 262(k)(7)
Common mistakes
Treating a dedicated switching study as a statutory requirement for interchangeability
the statute sets a risk standard for alternating or switching, not a prescribed study design. Teams that assume one fixed design either over-build a program they did not need or skip the risk showing entirely and lose the designation.
Filing 351(k) for a condition of use the reference product does not carry
the abbreviated pathway is bounded by the reference product's licensed conditions of use. A new indication, strength, dosage form, or route forces a standalone 351(a) application and erases the cost advantage the program was built on.
Running the exclusivity clocks off the wrong date
both the 4-year submission bar and the 12-year effective-licensure bar run from the date the reference product was first licensed, not from patent expiry or from a later supplement. Getting this wrong strands validation lots and commercial supply built for a launch that cannot legally happen.
When This Matters
- The 351(k) package leans on analytical comparability; the clinical study only has to close the residual uncertainty.
- We are not filing for interchangeability in the first cycle, so pharmacy substitution is off the table at launch.
- The biosimilar cannot be submitted until year four and cannot be licensed effective until year twelve.
Frequently Asked Questions
A biosimilar is highly similar to its reference product, while a generic is chemically identical to its reference listed drug. Generics are approved under section 505(j) of the FD&C Act on bioequivalence data; biosimilars are licensed under section 351(k) of the Public Health Service Act on analytical, toxicity, and comparative clinical evidence.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
